EXACT Sciences Gears Up for Earnings Reveal

By Patricia Miller


In this article

  • Loading...
  • Want to see what you should be buying? Check out our top picks.

EXACT Sciences eyes a pivotal moment with its upcoming Q3 earnings report. The firm excels in ESG ratings and revenue, but operational costs raise questions.

EXACT Sciences Forecasts Strong Annual Revenue Despite Operational Costs

EXACT Sciences is set to announce its Q3 earnings on November 1st, after market close. The firm specializes in various sectors, including Screening, Precision Oncology, and previously, COVID-19 testing.

Financial Metrics

  • Revenue: FactSet estimates place revenue at $616.8 million, with Screening contributing $462.3 million and Precision Oncology making up $154.3 million. COVID-19 testing shows no contribution, indicating a pivot or discontinuation in this area.

  • Expenses and Margins: The company is expected to spend $104.5 million on R&D and $191.3 million on Sales and Marketing. General and Administrative expenses stand at $215.8 million. The Non-GAAP gross margin is strong at 74.0%, but the GAAP Operating margin is in the negative at -13.7%.

  • Earnings Per Share (EPS): The EPS is expected to be negative at $0.47.

ESG Metrics

EXACT Sciences ranks as a Leader in ESG metrics with a Truvalue Labs adjusted insight score of 73, up 5 points quarter-over-quarter. Its MSCI score remains constant at 'A'.

Guidance for Fiscal Year

The company expects annual revenue to be between $2.44 billion and $2.47 billion. EBITDA is forecasted to be between $170.0 million and $180.0 million, with a margin of 7.0% to 7.3%.

Stock Performance and Volatility

EXACT Sciences' stock outperformed the S&P 500 and the Health Care sector (XLV), gaining 36.3% in Q3. Options trading suggests that investors expect about a 12.2% price move in the near term.

Past Performance

Revenue has surpassed consensus estimates in 18 of the past 20 quarters, while EPS has beaten estimates in 13 of the past 20 quarters.

Key Takeaways

1.     Revenue Streams: EXACT Sciences generates significant revenue from Screening and Precision Oncology.

2.     Operational Costs: High expenses, especially in G&A, are a concern and may be affecting the negative operating margin.

3.     ESG Leadership: The company is making strides in environmental, social, and governance aspects, which could be a long-term asset.

4.     Market Expectation: The market has high expectations for the stock, as evidenced by its Q3 performance and options activity.

5.     Consistent Performance: The history of frequently beating revenue and sometimes EPS estimates bodes well for the company.

EXACT Sciences shows promise in its revenue streams and ESG metrics but needs to manage its operational costs better to improve profitability.

Investors and market participants will be keenly watching the upcoming earnings report for these insights.

Sign up for Investing Intel Newsletter

BLUE-C Trial Sets New Standard in Colorectal Cancer Detection 

The next-generation Cologuard test from Exact Sciences Corp. sets a new standard for non-invasive colorectal cancer screening.

Here are the key takeaways from its pivotal BLUE-C trial:

Superior Performance

  • The test achieved 94% sensitivity and 91% specificity for detecting colorectal cancer, significantly outperforming the Fecal Immunochemical Testing (FIT) on both fronts.

High Specificity

  • With its high specificity rate, the test aims to reduce unnecessary follow-up colonoscopies, enhancing patient experience.

Robust Trial Data

  • The BLUE-C trial included over 20,000 subjects, making it one of the largest and most comprehensive colorectal cancer screening trials to date.

Advanced Detection

  • The test also showed higher sensitivity in detecting advanced precancerous lesions and high-grade dysplasia compared to FIT.

Additional Support

  • Further analysis confirmed that the next-generation Cologuard's performance metrics were equivalent to or better than the first-generation Cologuard test.

Upcoming Developments

  • Exact Sciences plans to submit the next-generation Cologuard for FDA approval and will release more data in the coming months.

Overall, the next-generation Cologuard test promises to be a game-changer in the early detection of colorectal cancer, offering higher accuracy and fewer false positives.

What you should read next:

Investing with Insight

Knowing where to invest is not easy. Bullish and bearish sentiment is always vying for control, and investors like you can very quickly become overwhelmed.

And yet, no matter what the wider stock market is doing, there are always little-known gems to uncover. 

One potential growth stock flying under the radar is a dynamic company operating at the forefront of the entertainment industry. This business is diverse and multifaceted and led by industry veterans with extensive experience in entertainment and investment.

This high-potential US stock is targeting India’s tech-hungry 1.4 billion people.

Internet and social media adoption in India is surging, and the country has the LARGEST youth population worldwide. Over 650M people are under 25 years old, and 850M are under 35 years old. 

With rising economic and educational prospects, the country is a hotbed for digital engagement.

Some highlights you’ll want to know include:

  • This is one of the fastest-growing creator-media companies in India and the United States.

  • This company reaches 1 billion global consumers every month.

  • India was the second-fastest-growing market in the influencer marketing space in 2022. 

  • Global influencer marketing spend is expected to reach $34 billion in 2023.

  • This company has posted nine consecutive quarters of YoY growth, representing a 33% CAGR using its repeatable content strategy.

  • This impressive small-cap has just appointed a former TikTok Country manager as its India Group CEO. 

Finally, this stock is analyst-backed with a potential 114% upside from the analyst initiation date.

If you're intrigued by this stock’s promising prospects, why not take a closer look?


In this article:



Author: Patricia Miller

This article does not provide any financial advice and is not a recommendation to deal in any securities or product. Investments may fall in value and an investor may lose some or all of their investment. Past performance is not an indicator of future performance.

Patricia Miller does not hold any position in the stock(s) and/or financial instrument(s) mentioned in the above article.

Patricia Miller has not been paid to produce this piece by the company or companies mentioned above.

Digitonic Ltd, the owner of ValueTheMarkets.com, does not hold a position or positions in the stock(s) and/or financial instrument(s) mentioned in the above article.

Digitonic Ltd, the owner of ValueTheMarkets.com, has not been paid for the production of this piece by the company or companies mentioned above.

Sign up for Investing Intel Newsletter